Compare KEX & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEX | PRAX |
|---|---|---|
| Founded | 1921 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 9.0B |
| IPO Year | 1994 | 2020 |
| Metric | KEX | PRAX |
|---|---|---|
| Price | $143.32 | $343.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $137.25 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 606.7K | 332.8K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.92 | N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | $7.61 | $7,758.26 |
| P/E Ratio | $96.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $79.52 | $35.21 |
| 52 Week High | $157.69 | $358.76 |
| Indicator | KEX | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.62 | 55.46 |
| Support Level | $140.14 | $282.49 |
| Resistance Level | $157.69 | $353.86 |
| Average True Range (ATR) | 3.85 | 20.50 |
| MACD | -0.50 | 0.17 |
| Stochastic Oscillator | 36.30 | 71.68 |
Kirby Corp is a domestic tank barge operator, transporting bulk liquid products throughout three United States coasts. The Company transports petrochemicals, liquid cargoes, inland waterway systems, and dry bulk cargoes. The Company conducts operations in two reportable business segments: The Marine transportation segment which provides marine transportation services, operating tank barges and towing vessels transporting bulk liquid products, and the Distribution and services segment, which provides after-market service, and genuine replacement parts for engines, transmissions, reduction gears, and power generation equipment used in oil and gas and commercial and industrial applications. The company's majority revenue is generated from the Marine Transportation segment.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.